Recombinant Factor VIIa (Eptacog Alfa): A Pharmacoeconomic Review of its Use in Haemophilia in Patients with Inhibitors to Clotting Factors VIII or IX

By Lyseng-Williamson Katherine A.   Plosker Greg L.  

PharmacoEconomics, Vol. 25, Iss. 12, 2007-01 ,pp. : 1007-1029

Adis International

Access to resources Recommend Favorite

Recombinant Factor VIIa (Eptacog Alfa): A Review of its Use in Congenital or Acquired Haemophilia and Other Congenital Bleeding Disorders

By Siddiqui M. Asif A.   Scott Lesley J.  

Drugs, Vol. 65, Iss. 8, 2005-01 ,pp. : 1161-1177

Adis International

Access to resources Recommend Favorite

Eptacog-alfa [activated recombinant factor VII] is an effective, well-tolerated therapy in haemophilia patients with inhibitors

By  

Inpharma, Vol. 1, Iss. 1572, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

The use of eptacog-α [recombinant factor VIIa] to treat acute intracerebral haemorrhage (ICH) may be highly cost effective in the UK

By  

Inpharma, Vol. 1, Iss. 1563, 2006-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Bivalirudin: Blood coagulation disorders treated with recombinant factor VIIa: case report

By  

Reactions Weekly, Vol. 1, Iss. 1375, 2011-01 ,pp. : 8-9

Adis International

Access to resources Recommend Favorite